Hormonal
Deficiency of Estrogen Receptor Beta (ERβ) in adipose tissue leads to increased body fat mass but improved systemic insulin sensitivity and glucose tolerance under high-fat diet conditions, mediated by enhanced PPARγ signaling.
This research suggests that the presence or absence of specific estrogen receptors (ERβ) in fat tissue dictates whether fat accumulation harms or helps metabolic health. While this is a genetic/mechanistic finding in mice and not a direct human intervention, it implies that simply reducing fat mass is not the only path to metabolic health; the hormonal environment of the fat tissue is critical.
Collectively, our data provide the first evidence that ERb-deficiency protects against diet-induced IR and glucose intolerance which involves an augmented PPARc signaling in adipose tissue.
Why this rating
Strong mechanistic evidence from knockout mice and in vitro models, but lacks human clinical trial data.
Source
Metabolic Actions of Estrogen Receptor Beta (ERβ) are Mediated by a Negative Cross-Talk with PPARγ
Anna Foryst‐Ludwig et al. · PLoS Genetics · 2008
DOI 10.1371/journal.pgen.1000108
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →